Kai Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kai Zeng has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Guodong Li
Department of General Surgery The Fourth Affiliated Hospital of Harbin Medical University Harbin China
1 shared publication - Jiufeng Wei
Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China; Bio-Bank of Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China
1 shared publication - Ming Liu
Department of General Surgery, The Fourth-Affiliated Hospital of Harbin Medical University Harbin, China
1 shared publication - Shuwei Dang
Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China; Bio-Bank of Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China
1 shared publication - Yuhui Zhou
Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China; Bio-Bank of Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2016
- Published by Wiley in Disease Markers
- Vol. 2016, 1-7
Discovery and Validation of Hypermethylated Markers for Colorectal Cancer
Colorectal carcinoma (CRC) is one of the most prevalent malignant tumors worldwide. Screening and early diagnosis are critical for the clinical management of this disease. DNA methylation changes have been regarded as promising biomarkers for CRC diagnosis. Here, we map DNA methylation profiling on CRC in six CRCs and paired normal samples using a 450 K bead array. Further analysis confirms the methylation status of candidates in two data sets from the Gene Expression Omnibus. Receiver operating characteristic (ROC) curves are calculated to determine the diagnostic performances. We identify 1549 differentially methylated regions (DMRs) showing differences in methylation between CRC and normal tissue. Two genes (ADD2andAKR1B1), related to the DMRs, are selected for further validation. ROC curves show that the areas under the curves ofADD2andAKR1B1are higher than that ofSEPT9, which has been clinically used as a screening biomarker of CRC. Our data suggests that aberrant DNA methylation ofADD2andAKR1B1could be potential screening markers of CRC.
- 1 January 2016
- Published by Wiley in Disease Markers
- Vol. 2016, 1-7
Open AccessDiscovery and Validation of Hypermethylated Markers for Colorectal Cancer
Colorectal carcinoma (CRC) is one of the most prevalent malignant tumors worldwide. Screening and early diagnosis are critical for the clinical management of this disease. DNA methylation changes have been regarded as promising biomarkers for CRC diagnosis. Here, we map DNA methylation profiling on CRC in six CRCs and paired normal samples using a 450 K bead array. Further analysis confirms the methylation status of candidates in two data sets from the Gene Expression Omnibus. Receiver operating characteristic (ROC) curves are calculated to determine the diagnostic performances. We identify 1549 differentially methylated regions (DMRs) showing differences in methylation between CRC and normal tissue. Two genes (ADD2andAKR1B1), related to the DMRs, are selected for further validation. ROC curves show that the areas under the curves ofADD2andAKR1B1are higher than that ofSEPT9, which has been clinically used as a screening biomarker of CRC. Our data suggests that aberrant DNA methylation ofADD2andAKR1B1could be potential screening markers of CRC.